Overview

GLP1 (S) is a catalog shorthand commonly used for semaglutide, a long-acting GLP-1 receptor agonist.
In research environments, semaglutide is used to study GLP-1R pharmacology, receptor signaling, and incretin-pathway biology in controlled experimental models.

Key identifiers

• Name: Semaglutide
• FDA substance registry: GINAS: Semaglutide
• CAS (commonly listed): 910463-68-2
• Registry link: PubChem: Semaglutide

Mechanistic context (research framing)

FDA labeling describes semaglutide as a human GLP-1 receptor agonist (GLP-1 analog).
A key “protraction” mechanism is albumin binding, enabled by fatty-acid side-chain modification (as described in labeling).

Research applications

• GLP-1R receptor assays: potency/efficacy, signaling kinetics, pathway bias (assay-dependent)
• Second messenger readouts: commonly cAMP-linked GPCR outputs
• Comparative profiling: benchmarking vs other GLP-1R agonists or multi-agonists in standardized panels

Human-use context (background only)

Semaglutide is the active ingredient in FDA-approved medicines including Ozempic (type 2 diabetes) and Wegovy (chronic weight management).
This is included strictly as scientific background and does not imply intended human use of RUO material.

• FDA label: Ozempic (semaglutide)
• FDA label: Wegovy (semaglutide)

Form, documentation & storage

• Form: often supplied as lyophilized powder for research workflows (confirm on COA)
• Documentation: use the lot COA for identity/purity and traceability
• General storage: sealed, dry, protected from light; follow SOPs and COA guidance

RUO disclaimer

For Research Use Only. Not for human or veterinary use. Not for diagnostic or therapeutic purposes.